Small Molecule Drug Discovery
The process of small molecule drug discovery can be complex and challenging. A typical workflow begins with hit identification and assay development, and carries through to preclinical candidate selection. High-throughput screening of drug candidates plays in essential role in the drug discovery process.
Promega offers a comprehensive selection of tools to accelerate drug discovery, based on an innovative, sensitive bioluminescence platform.
Rapid, sensitive luminescent methods for direct analyte measurement
Luminometers and Microplate Readers
Sensitive, high-throughput options for screening assays
SARS-CoV-2 Therapeutic and Vaccine Discovery
Assays and technologies to enable SARS-CoV-2 therapeutic and vaccine discovery and development.
Drug Discovery Conferences and Tradeshows
Promega scientists will be attending and speaking at key drug discovery conferences and tradeshows throughout the year. Join us to learn more about innovative solutions to accelerate your research.
|Event Name||2022 Dates||Location||Presentations|
|DDR, ATR & PARP Inhibitors Summit||January 25-27||Virtual||Video Presentation|
|3rd RAS/MAPK Pathway-Targeted Drug Discovery Summit||February 22-24||Virtual||Video Presentation
|2nd Targeted Protein Degradation (TPD) Summit Europe||March 15-17||London, UK||PDF Presentation|
|Next Generation Kinase Inhibitors Summit||March 29-31||Boston||Presentation|
|DDC (Drug Discovery Chemistry)||April 18-21||San Diego||PDF Presentation|
|2nd Ligase Targeting Drug Development Summit||April 26-28||Virtual||Video Presentation|
|2nd Induced Proximity-Based Drug Discovery Summit||May 11-12||Boston||PDF Presentation|
|4th RAS-Targeted Drug Development Summit||September 26-28||Boston||PDF Presentation|
|Induced Proximity Targeting Undruggables - Europe||October 11-12||Basel, Switzerland||PDF Presentation|
|5th Targeted Protein Degradation (TPD) Summit||October 25-27||Boston||PDF Presentation|
|Gene Therapy Analytical Development||November 28-December 1||Boston||Presentation|
|4th Annual Inflammasome Therapeutics Summit||November 29-December 1||Boston||Presentation|
|TPD Assay Development & Screening Summit||December 6-8||San Diego||Presentation|
About Small Molecule Drug Discovery
The pathway from identification of a novel drug candidate to preclinical trials can be complex. From screening compound libraries to measuring the interaction of a compound with its protein targets to examining the effects on cell health, the process of drug discovery relies on rapid, sensitive and high-throughput assays.
Technologies developed by Promega can help streamline the drug discovery process. NanoBRET™ target engagement assays quantitatively measure target occupancy and compound affinity in live cells. A comprehensive collection of CRISPR-edited cell lines and clones with popular targets fused to a small bioluminescent tag, supports these live-cell assays. In addition, these engineered cells are ideal for studying the effects of degrader compounds, such as PROTACs, IMiDs and molecular glues, in real time. Bioluminescence technology also forms the basis for assays to examine signaling pathways in kinase biology and to study oncogenesis, such as the RAS signaling pathway.
Our small molecule drug discovery products and technologies are supported by a range of services, including our partnerships with CROs and early access to the latest research products and technologies through our Elite Access program.
Webinar: Designing Successful Targeted Protein Degradation Assays
Our TPD experts address commonly asked questions and share best practices for developing degrader assays.
Webinar: Quantifying Inflammasome Activation and Target Engagement
Learn about a live-cell BRET target engagement assay for the NLRP3 inflammasome.
Video: Target Engagement Case Study
Learn how Aurelia Bioscience used NanoBRET™ technology to measure kinase target engagement under more physiologically relevant conditions.